RESUMEN
PURPOSE: To determine whether there is a benefit to adjuvant corneal cross-linking (CXL) for bacterial keratitis. METHODS: This is an outcome-masked, randomized controlled clinical trial. Consecutive patients presenting with a smear-positive bacterial ulcer at Aravind Eye Hospitals at Madurai, Pondicherry, and Coimbatore in India were enrolled. Study eyes were randomized to topical moxifloxacin 0.5% or topical moxifloxacin 0.5% plus CXL. The primary outcome of the trial was microbiological cure at 24 hours on repeat culture. Secondary outcomes included best spectacle corrected visual acuity at 3 weeks and 3 months, percentage of study participants with epithelial healing at 3 weeks and 3 months, infiltrate and/or scar size at 3 weeks and 3 months, 3-day smear and culture, and adverse events. RESULTS: Those randomized to CXL had 0.60 decreased odds of culture positivity at 24 hours (95% confidence interval [CI]: 0.10-3.50; P = 0.65), 0.9 logarithm of the minimum angle of resolution lines worse visual acuity (95% CI: -2.8 to 4.6; P = 0.63), and 0.41-mm larger scar size (95% CI: -0.48 to 1.30; P = 0.38) at 3 months. We note fewer corneal perforations or need for therapeutic penetrating keratoplasty in the CXL group. CONCLUSIONS: We were unable to confirm a benefit to adjuvant CXL in the primary treatment of moderate bacterial keratitis. However, CXL may reduce culture positivity and complication rates; therefore, a larger trial to fully evaluate this is warranted. TRIAL REGISTRATION: NCT02570321.
Asunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Reactivos de Enlaces Cruzados/uso terapéutico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Anciano , Antibacterianos/uso terapéutico , Bacterias/aislamiento & purificación , Colágeno/metabolismo , Terapia Combinada , Sustancia Propia/efectos de los fármacos , Sustancia Propia/metabolismo , Úlcera de la Córnea/metabolismo , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/fisiopatología , Infecciones Bacterianas del Ojo/metabolismo , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino/uso terapéutico , Riboflavina/uso terapéutico , Resultado del Tratamiento , Rayos Ultravioleta , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: Report of clinical/multimodal imaging outcomes of patients with syphilitic uveitis alternatively treated with intravenous(IV) ceftriaxone, due to unavailability of penicillin G. METHODS: Chart review of all cases of syphilitic uveitis presenting to Hospital São Geraldo/HC-UFMG and treated with intravenous ceftriaxone, between January and August 2014. Clinical, serological and ophthalmological data were collected. RESULTS: Twelve consecutive patients with syphilitic uveitis receiving IV ceftriaxone were identified. All 24 eyes had active intraocular inflammation on clinical examination. All patients received IV ceftriaxone (2-4 g daily) for 14-21 days, supplemented with oral corticosteroid as needed in 9 patients (75%), after documented clinical response. Improvement in intraocular inflammation was seen in all 24 eyes, with median best-corrected visual acuity (BCVA) increasing from 20/50 to 20/20, after a mean follow-up of 5.3 months. CONCLUSION: IV ceftriaxone may be an effective alternative for treatment of syphilitic uveitis, in the setting of unavailability of penicillin G.
Asunto(s)
Antibacterianos/administración & dosificación , Ceftriaxona/administración & dosificación , Coriorretinitis/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Sífilis/tratamiento farmacológico , Uveítis Posterior/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Coriorretinitis/diagnóstico , Coriorretinitis/fisiopatología , Terapias Complementarias , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/fisiopatología , Angiografía con Fluoresceína , Glucocorticoides/administración & dosificación , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Imagen Multimodal , Estudios Retrospectivos , Sífilis/diagnóstico , Sífilis/fisiopatología , Serodiagnóstico de la Sífilis , Tomografía de Coherencia Óptica , Uveítis Posterior/diagnóstico , Uveítis Posterior/fisiopatología , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: We described the change in visual acuity experienced by eyes successfully treated for bacterial keratitis. METHODS: This was a prospective cohort study of a subset of study participants who had previously enrolled in the Steroids for Corneal Ulcers Trial (SCUT). All study participants had been diagnosed with culture-proven bacterial keratitis before enrollment in SCUT and subsequently were randomized to adjunctive topical corticosteroids or placebo. During SCUT, we monitored study participants at enrollment, 3 weeks, 3 months, and 12 months. We invited a subset to complete a comprehensive eye examination approximately 4 years after enrollment in SCUT. Certified refractionists assessed best spectacle-corrected visual acuity (BSCVA) using the same protocol at each study visit. RESULTS: We examined 50 SCUT participants at 4 years after enrollment. Among those in this cohort, mean logMAR BSCVA at enrollment was 0.85 (Snellen equivalent, 20/160; 95% confidence interval [CI], 0.71-0.99). On average, visual acuity improved by 2.9 logMAR lines from enrollment to 3 weeks (P < 0.001), 1.2 lines from 3 weeks to 3 months (P = 0.002), and 0.8 lines from 3 to 12 months (P = 0.01). The BSCVA did not change significantly between 12 months and 4 years (0.04-line improvement, P = 0.88). After controlling for visual acuity at enrollment, BSCVA was not significantly different between the corticosteroid and placebo groups at 4 years (P = 0.53). CONCLUSIONS: Cases of bacterial keratitis may continue to demonstrate improvements in visual acuity up to 12 months following diagnosis, but further improvements are unlikely. These findings may guide the appropriate timing of surgical intervention in these patients. (ClinicalTrials.gov number, NCT00324168.).
Asunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Adulto , Anciano , Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/fisiopatología , Método Doble Ciego , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Prednisolona/uso terapéutico , Estudios Prospectivos , Quinolinas/uso terapéutico , Análisis de Regresión , Agudeza Visual/efectos de los fármacos , Agudeza Visual/fisiologíaAsunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Prednisolona/análogos & derivados , Recuperación de la Función/fisiología , Agudeza Visual/fisiología , Adulto , Anciano , Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/fisiopatología , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Prednisolona/uso terapéutico , Quinolinas/uso terapéuticoRESUMEN
PURPOSE: To compare the equivalence of moxifloxacin 0.5% with a combination of fortified cefazolin sodium 5% and tobramycin sulfate 1.3% eye drops in the treatment of moderate bacterial corneal ulcers. DESIGN: Randomized, controlled, equivalence clinical trial. PARTICIPANTS AND CONTROLS: Microbiologically proven cases of bacterial corneal ulcers were enrolled in the study and were allocated randomly to 1 of the 2 treatment groups. INTERVENTION: Group A was given combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate) and group B was given monotherapy (moxifloxacin 0.5%). MAIN OUTCOME MEASURES: The primary outcome variable for the study was percentage of the ulcers healed at 3 months. The secondary outcome variables were best-corrected visual acuity and resolution of infiltrates. RESULTS: Of a total of 224 patients with bacterial keratitis, 114 patients were randomized to group A, whereas 110 patients were randomized to group B. The mean ± standard deviation ulcer size in groups A and B were 4.2 ± 2 and 4.41 ± 1.5 mm, respectively. The prevalence of coagulase-negative Staphylococcus (40.9% in group A and 48.2% in group B) was similar in both the study groups. A complete resolution of keratitis and healing of ulcers occurred in 90 patients (81.8%) in group A and 88 patients (81.4%) in group B at 3 months. The observed percentage of healing at 3 months was less than the equivalence margin of 20%. Worsening of ulcer was seen in 18.2% cases in group A and in 18.5% cases in group B. Mean time to epithelialization was similar, and there was no significant difference in the 2 groups (P = 0.065). No serious events attributable to therapy were reported. CONCLUSIONS: Corneal healing using 0.5% moxifloxacin monotherapy is equivalent to that of combination therapy using fortified cefazolin and tobramycin in the treatment of moderate bacterial corneal ulcers. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Asunto(s)
Antibacterianos/uso terapéutico , Compuestos Aza/uso terapéutico , Cefazolina/uso terapéutico , Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Quinolinas/uso terapéutico , Tobramicina/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Compuestos Aza/administración & dosificación , Compuestos Aza/efectos adversos , Bacterias/aislamiento & purificación , Cefazolina/administración & dosificación , Cefazolina/efectos adversos , Córnea/efectos de los fármacos , Córnea/fisiopatología , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/fisiopatología , Evaluación de Medicamentos , Quimioterapia Combinada , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Soluciones Oftálmicas , Prevalencia , Estudios Prospectivos , Quinolinas/administración & dosificación , Quinolinas/efectos adversos , Equivalencia Terapéutica , Tobramicina/administración & dosificación , Tobramicina/efectos adversos , Resultado del Tratamiento , Agudeza Visual/efectos de los fármacos , Agudeza Visual/fisiologíaRESUMEN
Corneal ulcer is a devastating corneal disease which is potentially sight-threatening and conventionally is treated by topical antibiotics and in some cases with more invasive procedures such as keratoplasty. The aim of this study is to evaluate the efficacy of corneal collagen cross-linking in resistant corneal ulcers. Ten patients with resistant infectious corneal ulcers who had not responded properly to maximal treatment with topical and subconjunctival antibiotics were enrolled in the study and underwent classic corneal collagen cross-linking with riboflavin and UV-A under sterile conditions in the operating room and were followed up regularly. The result was healing and scar formation with improvement of vision in all patients except for two who underwent enucleation and tectonic penetrating keratoplasty. Corneal collagen cross-linking is a viable therapeutic option for treatment of corneal ulcers and can be used as an adjuvant for conventional treatment in resistant cases.
Asunto(s)
Colágeno/uso terapéutico , Úlcera de la Córnea/tratamiento farmacológico , Reactivos de Enlaces Cruzados/uso terapéutico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Administración Tópica , Adolescente , Adulto , Anciano , Colágeno/administración & dosificación , Úlcera de la Córnea/diagnóstico , Úlcera de la Córnea/fisiopatología , Reactivos de Enlaces Cruzados/administración & dosificación , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Agudeza Visual , Adulto JovenRESUMEN
PURPOSE: To compare the clinical course and effect of adjunctive corticosteroid therapy in Pseudomonas aeruginosa with those of all other strains of bacterial keratitis. METHODS: Subanalyses were performed on data collected in the Steroids for Corneal Ulcers Trial (SCUT), a large randomized controlled trial in which patients were treated with moxifloxacin and were randomly assigned to 1 of 2 adjunctive treatment arms: corticosteroid or placebo (4 times a day with subsequent reduction). Multivariate analysis was used to determine the effect of predictors, organism, and treatment on outcomes, 3-month best-spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size. The incidence of adverse events over a 3-month follow-up period was compared using Fisher's exact test. RESULTS: SCUT enrolled 500 patients. One hundred ten patients had P. aeruginosa ulcers; 99 of 110 (90%) enrolled patients returned for follow-up at 3 months. Patients with P. aeruginosa ulcers had significantly worse visual acuities than patients with other bacterial ulcers (P = 0.001) but showed significantly more improvement in 3-month BSCVA than those with other bacterial ulcers, adjusting for baseline characteristics (-0.14 logMAR; 95% confidence interval, -0.23 to -0.04; P = 0.004). There was no significant difference in adverse events between P. aeruginosa and other bacterial ulcers. There were no significant differences in BSCVA (P = 0.69), infiltrate/scar size (P = 0.17), and incidence of adverse events between patients with P. aeruginosa ulcers treated with adjunctive corticosteroids and patients given placebo. CONCLUSIONS: Although P. aeruginosa corneal ulcers have a more severe presentation, they appear to respond better to treatment than other bacterial ulcers. The authors did not find a significant benefit with corticosteroid treatment, but they also did not find any increase in adverse events. (ClinicalTrials.gov number, NCT00324168.).
Asunto(s)
Úlcera de la Córnea/tratamiento farmacológico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Glucocorticoides/uso terapéutico , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/aislamiento & purificación , Adulto , Antiinfecciosos/efectos adversos , Antiinfecciosos/uso terapéutico , Compuestos Aza/efectos adversos , Compuestos Aza/uso terapéutico , Úlcera de la Córnea/microbiología , Úlcera de la Córnea/fisiopatología , Método Doble Ciego , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Femenino , Fluoroquinolonas , Estudios de Seguimiento , Glucocorticoides/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino , Prednisolona/efectos adversos , Prednisolona/análogos & derivados , Prednisolona/uso terapéutico , Infecciones por Pseudomonas/microbiología , Infecciones por Pseudomonas/fisiopatología , Quinolinas/efectos adversos , Quinolinas/uso terapéutico , Resultado del Tratamiento , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: The purpose of this study was to determine the incidence of infectious endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia. METHODS: Retrospective chart review of 4690 consecutive intravitreal injections of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia. All patients had at least 6 weeks of follow-up. RESULTS: A total of 608 patients underwent intravitreal injection of antivascular endothelial growth factor medications during the study period. There were 428 injections of pegaptanib sodium, 1841 injections of bevacizumab, and 2421 injections of ranibizumab. There were no cases of infectious endophthalmitis. The per-injection infection rate was 0.0% (95% confidence interval, 0.0-0.06%). CONCLUSION: The incidence of infectious endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using 2% topical lidocaine gel anesthesia is low.
Asunto(s)
Anestesia Local/métodos , Anestésicos Locales/administración & dosificación , Inhibidores de la Angiogénesis/administración & dosificación , Endoftalmitis/epidemiología , Infecciones Bacterianas del Ojo/epidemiología , Lidocaína/administración & dosificación , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Anticuerpos Monoclonales Humanizados/administración & dosificación , Aptámeros de Nucleótidos/administración & dosificación , Bevacizumab , Endoftalmitis/microbiología , Endoftalmitis/fisiopatología , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/fisiopatología , Humanos , Incidencia , Inyecciones Intravítreas , Ranibizumab , Estudios Retrospectivos , Factores de Tiempo , Agudeza Visual/fisiologíaRESUMEN
PURPOSE: To identify factors that influence the outcome of patients with severe infectious corneal ulcers. METHOD: A retrospective review was performed of the hospital records of all such patients admitted to the Doheny Eye Hospital during a 30 month period. Outcome variables examined were change in visual acuity, duration of hospitalization, hospital charges, and percentage of patients who required penetrating keratoplasty. RESULTS: Sixty-two ulcers were included. An organism was identified and antibiotic sensitivities established in 52 patients (84%). Inpatient therapy involved a combination of fortified aminoglycoside and cephalosporin antibiotics in 39 patients (63%) and was found to be appropriate on the basis of sensitivity studies in 49 (94%) of 52 patients. Inappropriate initial treatment was related to increased hospital charge (P = 0.024) as well as increased risk of penetrating keratoplasty (P = 0.001). CONCLUSIONS: Appropriate initial therapy is most critical in the course of serious corneal ulcers, and aggressive, broad-spectrum antibiotic coverage is advocated.